The Technical Analyst
Kodiak Sciences Inc [KOD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kodiak Sciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.61% $3.47
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 182.20 mill |
| EPS: | -4.97 |
| P/E: | -0.700 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 52.51 mill |
| Avg Daily Volume: | 0.938 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.700 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -0.700 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.982 (-42.89%) $-1.488 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.76 - 4.18 ( +/- 20.43%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-30 | Baker Bros. Advisors Lp | Buy | 40 000 | Non-Qualified Stock Options (right to buy) |
| 2023-06-30 | Yang Taiyin | Buy | 40 000 | Stock Option (Right to Buy) |
| 2023-06-30 | Profusek Robert | Buy | 40 000 | Stock Option (Right to Buy) |
| 2023-06-30 | Levy Richard S | Buy | 40 000 | Stock Option (Right to Buy) |
| 2023-06-30 | Dahiyat Bassil I | Buy | 40 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 96.14 |
| Last 99 transactions |
| Buy: 3 824 931 | Sell: 1 385 823 |
Forecast:
16:00 - $3.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.48
Forecast 2: 16:00 - $3.48
Forecast 3: 16:00 - $3.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.47 (-3.61% ) |
| Volume | 0.567 mill |
| Avg. Vol. | 0.938 mill |
| % of Avg. Vol | 60.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KOD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $5.23 | N/A | Active |
|---|
KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-28 06:30:00 - Press Release
Kodiak Sciences Announces Recent Business Highlights And Fourth Quarter And Full Year 2023 Financial Results
Three clinical programs present diversified opportunities in and outside the existing anti-vegf market and are being progressed toward phase 3 value inflection points new phase 3 glow2 study of tarcocimab in diabetic retinopathy actively recruiting phase 1b study of ksi-101 planned for 2q2024 with the goal of initiating dual pivotal studies in 2024 new phase 3 daybreak study in wet amd to include ksi-501 and tarcocimab investigational groups versus aflibercept targeted to start recruitment mid-2024 following completion of fda discussions investor day to be scheduled after on-going regulatory interactions completed palo alto, calif. , march 28, 2024 /prnewswire/ -- kodiak sciences inc...
2024-03-26 06:15:00 - Press Release
Kodiak Sciences To Report Fourth Quarter And Full-year 2023 Financial Results And Host Business Updates Webcast On March 28, 2024
Palo alto, calif. , march 26, 2024 /prnewswire/ -- kodiak sciences inc. (nasdaq: kod), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on thursday, march 28, 2024.
2024-01-30 06:30:00 - Press Release
Kodiak Sciences Announces Upcoming Presentation Of First Time Results Of Ksi-501abc Phase 1 Study At The Angiogenesis, Exudation, And Degeneration 2024 Virtual Meeting
Palo alto, calif. , jan. 30, 2024 /prnewswire/ -- kodiak sciences inc. (nasdaq: kod), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the ksi-501abc phase 1 study will be presented at the angiogenesis, exudation, and degeneration 2024 virtual meeting.
2024-01-04 16:15:00 - Press Release
Kodiak Sciences To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Palo alto, calif. , jan. 4, 2024 /prnewswire/ -- kodiak sciences inc. (nasdaq: kod), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd annual j.p.
2023-11-21 16:15:00 - Press Release
Kodiak Sciences To Present At The 6th Annual Evercore Isi Healthconx Conference
Palo alto, calif. , nov. 21, 2023 /prnewswire/ -- kodiak sciences inc. (nasdaq: kod), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6th annual evercore isi healthconx conference in miami, florida on wednesday, november 29, 2023, at 3:25 p.m.
Latest News
2024-04-04 13:11:04 - Zacks Investment Research
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
2024-04-01 13:00:54 - Zacks Investment Research
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
2024-03-28 20:57:08 - Seeking Alpha
Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript
2024-03-26 06:15:00 - PRNewsWire
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
PALO ALTO, Calif. , March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024.
2024-02-01 12:56:04 - Zacks Investment Research
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
2024-01-04 16:15:00 - PRNewsWire
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P.
2023-11-21 16:15:00 - PRNewsWire
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
PALO ALTO, Calif. , Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023, at 3:25 p.m.
2023-11-15 09:02:13 - Zacks Investment Research
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
2023-09-08 06:00:00 - PRNewsWire
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PALO ALTO, Calif. , Sept. 8, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023, at 12:55 p.m.
2023-08-16 11:44:07 - Zacks Investment Research
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.